Literature DB >> 11586264

Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells.

J Y Yeh1, W J Huang, S F Kan, P S Wang.   

Abstract

PURPOSE: Digitalis or cardiac glycosides have been noted to induce tumor static or oncolytic effects in various types of cancer. We evaluated the effects and underlying mechanisms of cardiac glycosides, including digoxin, digitoxin and ouabain, on the proliferation of hormone dependent and independent prostate cancer cell lines.
MATERIALS AND METHODS: Cell proliferation of the 3 human prostate cancer cell lines LNCaP, DU145 and PC3 was measured by 3-(4,5-dimethylthiazol-2-yle)2,5-diphenyltetralozium bromide (Sigma Chemical Co., St. Louis, Missouri) colorimetric assay. The cytotoxic effects of digitalis on prostate cancer cells were determined by lactate dehydrogenase measurements of the culture medium. Intracellular Ca2+ was measured by a dual wavelength spectrometer system. The percent of apoptotic cells after digitalis treatment was measured by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling and flow cytometry.
RESULTS: Digoxin, digitoxin and ouabain significantly inhibited the proliferation of LNCaP, DU145 and PC3 cells at a dose of 1 or 10 microM. after 1 to 4 days of culture. Cytotoxicity of digitalis on the DU145 and LNCaP cells was dose dependent but cytotoxicity was not obvious in PC3. Digitalis (1 microM.) significantly increased intracellular Ca2+ in LNCaP and DU145 after 12 hours of culture but PC3 cells needed a 24-hour treatment to show any effect. In the apoptosis measurement digitalis at a dose of 1 and 10 microM. also significantly increased the percent of apoptotic cells in the LNCaP, DU145 and PC3 cell lines. Normal control human glomerular epithelial cells showed no response to digitalis treatment at all tested doses.
CONCLUSIONS: Digitalis may inhibit the proliferation of prostate cancer cell lines, although the 3 cell lines showed varied sensitivity to digitalis. These effects are possibly the result of a mechanism involving sustained elevation of the concentration of intracellular Ca2+ and of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586264

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

1.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Authors:  Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

2.  Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers.

Authors:  Tatjana Mijatovic; Véronique Mathieu; Jean-François Gaussin; Nancy De Nève; Fabrice Ribaucour; Eric Van Quaquebeke; Patrick Dumont; Francis Darro; Robert Kiss
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.

Authors:  Bishoy A Gayed; Katherine J O'Malley; Jan Pilch; Zhou Wang
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

4.  Influence of Sugar Amine Regiochemistry on Digitoxigenin Neoglycoside Anticancer Activity.

Authors:  Jianjun Zhang; Larissa V Ponomareva; Nitin S Nandurkar; Yaxia Yuan; Lei Fang; Chang-Guo Zhan; Jon S Thorson
Journal:  ACS Med Chem Lett       Date:  2015-08-12       Impact factor: 4.345

5.  A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

Authors:  Jianqing Lin; Tingting Zhan; Danielle Duffy; Jean Hoffman-Censits; Deborah Kilpatrick; Edouard J Trabulsi; Costas D Lallas; Inna Chervoneva; Kimberly Limentani; Brooke Kennedy; Sarah Kessler; Leonard Gomella; Emmanuel S Antonarakis; Michael A Carducci; Thomas Force; Wm Kevin Kelly
Journal:  Am J Cancer Ther Pharmacol       Date:  2014-09-07

6.  Is digoxin use for cardiovascular disease associated with risk of prostate cancer?

Authors:  Jonathan L Wright; Philip D Hansten; Janet L Stanford
Journal:  Prostate       Date:  2013-09-21       Impact factor: 4.104

7.  Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin.

Authors:  Peiying Yang; Carrie Cartwright; Ekem Efuet; Stanley R Hamilton; Ignacio Ivan Wistuba; David Menter; Crandell Addington; Imad Shureiqi; Robert A Newman
Journal:  Mol Carcinog       Date:  2012-10-16       Impact factor: 4.784

8.  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors:  Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

9.  Changes in sodium pump expression dictate the effects of ouabain on cell growth.

Authors:  Jiang Tian; Xin Li; Man Liang; Lijun Liu; Joe X Xie; Qiqi Ye; Peter Kometiani; Manoranjani Tillekeratne; Runming Jin; Zijian Xie
Journal:  J Biol Chem       Date:  2009-03-27       Impact factor: 5.157

10.  Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells in vitro.

Authors:  C I Delebinski; S Georgi; S Kleinsimon; M Twardziok; B Kopp; M F Melzig; G Seifert
Journal:  Cell Prolif       Date:  2015-08-24       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.